DiscoverPeerVoice Oncology & Haematology VideoHarry Paul Erba, MD, PhD - New Tools, New Considerations: Optimizing Our Approaches to Managing Newly Diagnosed FLT3-Mutant AML
Harry Paul Erba, MD, PhD - New Tools, New Considerations: Optimizing Our Approaches to Managing Newly Diagnosed FLT3-Mutant AML

Harry Paul Erba, MD, PhD - New Tools, New Considerations: Optimizing Our Approaches to Managing Newly Diagnosed FLT3-Mutant AML

Update: 2024-11-15
Share

Description

Visit https://www.peervoice.com/TUH860 to view the entire programme with slides. After completing “Harry Paul Erba, MD, PhD - New Tools, New Considerations: Optimizing Our Approaches to Managing Newly Diagnosed FLT3-Mutant AML”, participants will be able to: Recall clinical trial data evaluating first- and second-generation FLT3 inhibitors in the management of newly diagnosed FLT3-mutant acute myeloid leukemia (AML); Implement best practice approaches to using FLT3 inhibitors in practice, including selecting between therapeutics and utilizing recommended dose schedules; and Formulate adverse event management strategies for patients receiving treatment with a FLT3 inhibitor, including monitoring and supportive treatment.
Comments 
In Channel
loading
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

Harry Paul Erba, MD, PhD - New Tools, New Considerations: Optimizing Our Approaches to Managing Newly Diagnosed FLT3-Mutant AML

Harry Paul Erba, MD, PhD - New Tools, New Considerations: Optimizing Our Approaches to Managing Newly Diagnosed FLT3-Mutant AML

PeerVoice